이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

Development and Prospective Validation of an AI-Based Diagnostic Model for Hepato-Pancreato-Biliary Diseases

The rapid advancement of artificial intelligence (AI) has expanded its applications in healthcare, particularly in diagnostic assistance, intelligent triage, and patient interaction. Hepatobiliary and pancreatic diseases (such as liver cancer, pancreatic cancer, cirrhosis) are characterized by insidious onset, rapid progression, low early-diagnosis rates, and poor prognosis. However, grassroots medical institutions in China face challenges including physician shortages, variable patient health literacy, and incomplete initial information collection, leading to high misdiagnosis/missed diagnosis risks.

Recent breakthroughs in large language models (LLMs) and multi-agent systems (MAS) offer new solutions. LLMs enable advanced natural language processing, while MAS coordinates specialized agents for complex decision-making. Integrating MAS with medical LLMs could create intelligent pre-consultation systems that systematically collect patient symptoms, risk factors, family history, and lifestyle data to enhance diagnostic efficiency.

This study aims to develop a MAS-based pre-consultation system for hepatobiliary-pancreatic diseases featuring four specialized agents ("guidance agent," "medical history agent," "risk assessment agent," and "summary generation agent"). The system will simulate clinical reasoning to generate structured diagnostic reports for physicians.

Research Objectives:

Develop a specialized multi-agent framework combining LLMs to simulate clinical diagnostic logic and standardize symptom collection Enhance pre-consultation data integrity through intelligent dialogue focusing on key disease indicators Generate structured diagnostic summaries highlighting critical symptoms and risk factors Establish foundation for clinical validation and application through expert evaluation and user feedback This pre-diagnostic tool will assist physicians rather than replace clinical judgment, promoting safe, effective AI applications in early disease screening and tiered healthcare systems.

연구 개요

상세 설명

With the rapid development of artificial intelligence (AI) technologies, their applications in the healthcare field have become increasingly widespread, particularly demonstrating significant potential in diagnostic assistance, intelligent triage, and patient interaction. Hepatobiliary and pancreatic diseases (e.g., liver cancer, pancreatic cancer, bile duct cancer, cirrhosis) are characterized by insidious onset, rapid progression, low early diagnostic rates, and poor prognosis. Clinical diagnosis and treatment demand high requirements for early recognition and precise evaluation. However, grassroots medical institutions in China commonly face challenges such as insufficient specialist physicians, heterogeneous patient health literacy, and inadequate initial information collection during first visits, leading to a high risk of missed or incorrect diagnoses and delays in optimal intervention timing.

In recent years, large language models (LLMs) have achieved breakthrough advancements in natural language understanding and generation, providing a technical foundation for constructing intelligent, personalized medical dialogue systems. Multi-agent systems (MAS) simulate collaborative workflows among multiple specialized roles, enabling more complex and structured decision-making processes with notable advantages in task decomposition, knowledge integration, and dynamic reasoning. Integrating multi-agent architectures with medical LLMs offers the potential to develop intelligent pre-consultation systems with domain-specific expertise, enabling systematic collection and preliminary analysis of critical patient information-including symptoms, risk factors, family history, and lifestyle-to enhance the efficiency and completeness of medical consultations.

This study aims to develop an intelligent pre-consultation LLM system for hepatobiliary and pancreatic diseases based on a multi-agent architecture. By establishing clearly defined "guidance agents," "medical history collection agents," "risk assessment agents," and "physician summary generation agents," the system will simulate clinical diagnostic logic, proactively guide patients through structured disease presentations, and automatically generate initial diagnostic reports compliant with clinical standards for physician reference. This system seeks to assist grassroots physicians in improving early recognition of hepatobiliary and pancreatic diseases, optimize outpatient resource allocation, and enhance patient healthcare experiences.

Research Objectives:

This study aims to design, develop, and preliminarily validate an intelligent pre-consultation LLM system for hepatobiliary and pancreatic diseases based on a multi-agent architecture, exploring its feasibility and potential value in clinical pre-consultation scenarios. Specific objectives include:

Establishing a specialized multi-agent collaborative framework: Leveraging LLM technology, design a multi-agent system capable of division of labor and collaboration, incorporating modules such as guidance, medical history collection, preliminary risk screening, and report generation. By simulating the diagnostic logic and reasoning pathways of clinical physicians, the system will achieve systematic, structured information collection for hepatobiliary and pancreatic disease-related symptoms.

Enhancing the completeness and accuracy of pre-consultation information: Through intelligent dialogue, proactively guide patients to review and articulate their medical history, prioritizing key risk factors for hepatobiliary and pancreatic diseases-including jaundice, abdominal pain, weight loss, alcohol consumption history, history of viral hepatitis, and family history of cancer-to improve patient self-reporting completeness and reduce information omissions caused by memory biases or unclear expression.

Generating structured initial diagnostic assistance reports: Automatically integrate patient-reported symptoms and medical history into pre-consultation summaries adhering to clinical documentation standards, highlighting critical physical signs and risk alerts. This will assist physicians in rapidly grasping patient profiles, shortening outpatient consultation times, and improving diagnostic efficiency.

Laying the foundation for subsequent clinical validation and application: Through small-scale simulation testing and expert evaluation, preliminarily verify the system's usability and clinical alignment, collect feedback from physicians and patients, and optimize interactive workflows. This will provide scientific evidence and ethical compliance support for future prospective clinical studies and product development.

This research is not intended for direct clinical diagnosis or treatment decisions but rather as an information-assistance tool for physicians prior to consultations. It aims to promote safe, effective, and equitable applications of AI in the early screening of hepatobiliary and pancreatic diseases and tiered healthcare delivery systems.

연구 유형

관찰

등록 (추정된)

400

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

  • 성인
  • 고령자

건강한 자원 봉사자를 받아들입니다

샘플링 방법

확률 샘플

연구 인구

The study population will consist of adult outpatients (aged 18-75 years) with suspected or confirmed hepatobiliary and pancreatic diseases (e.g., liver cancer, pancreatic cancer, cholangiocarcinoma, cirrhosis) who are scheduled for routine outpatient consultations at participating healthcare institutions. Participants must demonstrate sufficient cognitive function (Mini-Mental State Examination [MMSE] score ≥24) and proficiency in Mandarin or English to ensure effective interaction with the AI multi-agent system. All individuals must provide written informed consent and be capable of completing all study procedures, including structured interactions with the AI system and follow-up physician evaluations.

설명

Inclusion Criteria:

  • Age and Gender: Patients aged 18 to 75 years, of either sex.
  • Clinical Diagnosis Requirements: Suspected or confirmed hepatobiliary or pancreatic diseases (e.g., liver cancer, pancreatic cancer, cholangiocarcinoma, cirrhosis) based on preliminary clinical evaluation.
  • Ability to provide a complete medical history and symptoms for AI system interaction.
  • Cognitive and Physical Capacity:
  • Sufficient cognitive function to complete interactions with the AI multi-agent system independently (verified by Mini-Mental State Examination [MMSE] score ≥24).
  • Proficiency in Mandarin or English to ensure accurate communication with the system.
  • Consent and Compliance: Willingness to participate and provide written informed consent.
  • Ability to complete all study procedures, including physician consultations and follow-up assessments.
  • Clinical Workflow Compatibility: Scheduled for outpatient consultation at participating healthcare facilities.

Exclusion Criteria:

  • Patients with life-threatening conditions requiring immediate intervention (e.g., acute hepatic failure, severe hemorrhage).
  • Presence of severe cardiovascular or cerebrovascular diseases that may interfere with study participation.
  • Cognitive or Communication Barriers:
  • Cognitive impairment (MMSE score <24) or language barriers preventing effective interaction with the AI system.
  • Psychiatric disorders or altered mental status affecting decision-making capacity.
  • Prior or Concurrent Participation:
  • Enrollment in other interventional clinical trials that may confound the study outcomes.
  • Current use of experimental diagnostic tools or AI systems outside the study protocol.
  • Technical or Logistical Constraints:
  • Inability to access or operate electronic devices required for AI system interaction (e.g., touchscreen terminals, mobile apps).
  • Lack of stable internet connectivity for system access.
  • Ethical or Legal Restrictions: Pregnancy or lactation (to avoid potential risks not directly related to the study).

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

코호트 및 개입

그룹/코호트
개입 / 치료
Experimental Group 1
Patients in this group will first complete a full interaction with the multi-agent system described above until the Arbiter confirms the medical record is error-free. The system will then generate a structured "Case Characteristics" summary and an initial diagnostic recommendation produced by the Oracle. However, this complete AI-generated output will not be displayed to the subsequent attending physician. The physician will then conduct an independent routine consultation following standard clinical protocols. The medical records generated by the physician are solely for maintaining the integrity of clinical workflows and will not be used as evaluation metrics for this study. The core assessment objective for this group is to evaluate the concordance between the AI-generated final medical records and the predefined gold standard.
Patients first complete a full interaction with the multi-agent system until the Arbiter confirms the medical record is error-free. The system then generates a structured "Case Characteristics" (CC) summary and preliminary diagnostic recommendations via the Oracle Agent. However, the complete AI output is not displayed to the subsequent attending physician. The physician conducts an independent consultation following standard clinical protocols, and their medical records are solely used to maintain clinical workflow integrity and are not evaluated as part of this study. The core assessment objective for this group is the concordance between the AI-generated final medical records and the gold-standard reference.
Experimental Group 2
Patients in this group will complete the interaction with the multi-agent system and confirm the final "Case Characteristics" (CC). The system will then push this structured CC summary (excluding the Oracle's diagnostic recommendations to avoid excessive guidance) to the attending physician's electronic workstation in a standardized format. Prior to the formal consultation, physicians may refer to this summary to adjust their interview priorities, verify information accuracy, or supplement missing details. The medical records written by the physicians will serve as the primary evaluation metrics for this group.
After patients finalize the CC through interaction with the multi-agent system, the structured "Case Characteristics" (excluding Oracle-generated diagnostic advice to avoid over-guidance) are pushed in a standardized format to the corresponding physician's electronic workstation. Physicians may reference this summary before formal consultation to adjust their questioning focus, verify information accuracy, or supplement missing details. The physician's final written medical record serves as the primary evaluation object for this group.
Control Group
This group will exclude AI intervention entirely. Physicians will independently complete the consultation and documentation from scratch, serving as the baseline reference for evaluating AI system performance.

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Concordance Rate Between AI-Generated Medical Records and Gold Standard
기간: From enrollment through completion of the index outpatient visit and chart assessment, assessed up to 7 days
Proportion of AI-generated "Case Characteristics" summaries that match the gold standard (established by expert panels) in key diagnostic elements (e.g., symptom description, risk factors, physical findings).
From enrollment through completion of the index outpatient visit and chart assessment, assessed up to 7 days
Diagnostic Accuracy of Physician Documentation With AI Summary Reference
기간: From enrollment through completion of the index outpatient visit and chart assessment, assessed up to 7 days
Proportion of physician-completed medical records in Experimental Group 2 that meet predefined quality criteria (completeness, diagnostic relevance, alignment with gold standard).
From enrollment through completion of the index outpatient visit and chart assessment, assessed up to 7 days
Proportion of physician medical records meeting predefined quality criteria without AI support
기간: From enrollment through completion of the index outpatient visit and chart assessment, assessed up to 7 days
Proportion of physician-completed medical records that meet predefined quality criteria (completeness, diagnostic relevance, alignment with gold standard) in the absence of AI assistance.
From enrollment through completion of the index outpatient visit and chart assessment, assessed up to 7 days

2차 결과 측정

결과 측정
측정값 설명
기간
Average physician consultation duration
기간: From enrollment through completion of the index outpatient visit and chart assessment, assessed up to 7 days
Comparison of average consultation times across study groups.
From enrollment through completion of the index outpatient visit and chart assessment, assessed up to 7 days
Average pre-consultation preparation time for physicians
기간: From enrollment through completion of the index outpatient visit and chart assessment, assessed up to 7 days
Time spent by physicians reviewing AI-generated case summaries before consultation.
From enrollment through completion of the index outpatient visit and chart assessment, assessed up to 7 days
Patient satisfaction measured by validated questionnaires
기간: From enrollment through completion of the index outpatient visit and chart assessment, assessed up to 7 days
Patient-reported experience measured via validated satisfaction questionnaires. Scores range from 0 to 100; higher scores indicate greater satisfaction, assessing ease of AI interaction and perceived care quality.
From enrollment through completion of the index outpatient visit and chart assessment, assessed up to 7 days
Physician satisfaction with AI workflow
기간: From enrollment through completion of the index outpatient visit and chart assessment, assessed up to 7 days
Physician survey evaluating perceived efficiency, usability, and clinical utility of AI tools. Survey scores range from 0 to 100; higher survey scores represent better satisfaction with the AI system.
From enrollment through completion of the index outpatient visit and chart assessment, assessed up to 7 days
Frequency of AI-related adverse events and workflow disruptions
기간: From enrollment through completion of the index outpatient visit and chart assessment, assessed up to 7 days
Documentation of AI-related errors, workflow disruptions, or safety concerns. Count of participants experiencing safety or workflow issues.
From enrollment through completion of the index outpatient visit and chart assessment, assessed up to 7 days
System Usability Scale (SUS) scores for the AI interface
기간: From enrollment through completion of the index outpatient visit and chart assessment, assessed up to 7 days
System Usability Scale (SUS) is a standardized usability questionnaire; total score ranges from 0 to 100. Higher SUS scores correspond to better perceived usability of the AI interface, completed by physicians and patients.
From enrollment through completion of the index outpatient visit and chart assessment, assessed up to 7 days

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

수사관

  • 연구 의자: ding yuan, doctor, Second Affiliated Hospital, School of Medicine, Zhejiang University

간행물 및 유용한 링크

연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (추정된)

2026년 8월 15일

기본 완료 (추정된)

2026년 11월 30일

연구 완료 (추정된)

2026년 11월 30일

연구 등록 날짜

최초 제출

2026년 3월 4일

QC 기준을 충족하는 최초 제출

2026년 7월 15일

처음 게시됨 (실제)

2026년 7월 21일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 7월 21일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 7월 15일

마지막으로 확인됨

2025년 12월 1일

추가 정보

이 연구와 관련된 용어

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

아니요

IPD 계획 설명

Patient Privacy and Confidentiality:

IPD contains sensitive personal health information (e.g., medical history, genetic data, diagnostic results), which could risk re-identification even after anonymization. Sharing such data might violate ethical obligations under the Declaration of Helsinki and local regulations (e.g., GDPR, HIPAA).

Informed Consent Limitations:

Participants provided consent for data use within the scope of this specific study. Broad sharing of IPD for secondary purposes (e.g., unrelated research) was not explicitly authorized in the consent process, raising ethical and legal concerns.

Data Ownership and Governance:

Data may be governed by institutional or national policies restricting external access (e.g., Chinese data sovereignty laws). Sharing IPD could conflict with agreements between the study sponsor, healthcare providers, and regulatory bodies.

Risk of Misinterpretation:

Contextual or methodological details critical to interpreting IPD (e.g., AI system workfl

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

간질환에 대한 임상 시험

AI Integration type 1에 대한 임상 시험

구독하다